Tulisokibart

Phase 2Small molecule

Merck & Co.

Tulisokibart is one of 101 small molecule programs targeting ART. It is currently in Phase 2.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

ARTCompleted

Interstitial Lung DiseaseActive, not recruiting

Rheumatoid ArthritisRecruiting

ARTPhase 1

Completed

Interstitial Lung DiseasePhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Recruiting

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actos

Takeda

Preclinical

2 2

Celexa

AbbVie

Preclinical

1 3

Tulisokibart

Merck & Co.

Phase 2

1 4

Voltaren

Cataflam

Plaquenil

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 9

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Disalcid

JJoslin Diabetes Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

Hidradenitis Suppurativa

NCT06956235

Q3 2029

Phase 2Active, not recruiting

Interstitial Lung Disease

NCT05270668

Phase 2Recruiting

Rheumatoid Arthritis

NCT07176390

Q1 2030

Phase 2Recruiting

Psoriatic Arthritis

NCT07486960

Phase 2Recruiting

Radiographic Axial Spondyloarthritis

NCT07133633

Q4 2037

Phase 3Recruiting

Crohn Disease

NCT06651281

Clinical

Trials by Indication[1]

ART2 trials

Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06575595·60 enrolled

A Study of MK-7240 in Healthy Participants (MK-7240-009)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07405177·330 enrolled

Crohn Disease2 trials

A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06651281·1,380 enrolled

A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT05013905·55 enrolled

Single Dose1 trial

Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06829225·48 enrolled

Interstitial Lung Disease1 trial

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT05270668·154 enrolled

Rheumatoid Arthritis1 trial

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07176390·182 enrolled

4 more indications

Hidradenitis Suppurativa1 trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06956235·149 enrolled

Psoriatic Arthritis1 trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Psoriatic Arthritis.

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07486960·140 enrolled

Radiographic Axial Spondyloarthritis1 trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07133633·315 enrolled

Ulcerative Colitis1 trial

A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04996797·178 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Tulisokibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tulisokibart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tulisokibart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Tulisokibart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2029

Q1 2030

Q4 2037

Trials by Indication[1]

ART2 trials

Crohn Disease2 trials

Single Dose1 trial

Interstitial Lung Disease1 trial

Rheumatoid Arthritis1 trial

Hidradenitis Suppurativa1 trial

Psoriatic Arthritis1 trial

Radiographic Axial Spondyloarthritis1 trial

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News